# Sun Pharmaceutical Industries ‚Äì Operations & Project Management Analysis (MB932)

**Module:** MB932 ‚Äì Operations & Project Management  
**University:** University of Strathclyde Business School  
**Focus:** Operational Excellence, Quality Management, Hayes & Wheelwright Model, Value Chain Improvement  
**Document:** OPM.docx  

---

## üìå Project Overview

This project presents a strategic operations analysis of **Sun Pharmaceutical Industries Ltd**, one of the world‚Äôs largest generic and specialty pharmaceutical companies.  
It evaluates Sun Pharma‚Äôs operational maturity, customer performance, internal management systems, quality issues, supply chain challenges, and project management weaknesses.

The assignment combines **operations management theory**, **project management frameworks**, and **evidence-based recommendations** to propose a path toward operational excellence and sustainable growth.

---

# üß© Part A ‚Äî Operational Strategy Analysis

## 1Ô∏è‚É£ Hayes & Wheelwright Four-Stage Model Positioning

Sun Pharma is positioned at **Stage 3 ‚Äì Internally Supportive**, supported by:

- Lean manufacturing adoption  
- Vertically integrated supply chain  
- Strong R&D investment  
- Global regulatory approvals (FDA, EMA, WHO)  
- Strategic partnerships and acquisitions  

### **Why not Stage 4?**
- Recurring FDA quality violations  
- Customer-facing digital gaps  
- Overdependence on US generics market  
- Limited patient-centric innovation  

Sun Pharma supports business strategy well but does not yet **shape market competition** ‚Äî the hallmark of Stage 4.

---

## 2Ô∏è‚É£ External Customer Perspective

### **Strengths**
- Affordable pricing through economies of scale  
- Wide portfolio across therapeutic areas  
- Strong distribution in global markets  
- Good delivery reliability  

### **Weaknesses**
- Product recalls harming trust  
- Limited digital engagement with patients  
- Transparency gaps around quality issues  

**Customer Perception Summary:**  
High affordability and access, but quality lapses pose significant risk to long-term trust.

---

## 3Ô∏è‚É£ Internal Management Perspective

### **Strengths**
- Mature lean practices  
- Strong financial capacity  
- R&D-driven differentiation  
- Vertically integrated operations  

### **Weaknesses**
- Repeated FDA compliance issues  
- Manual processes in some facilities  
- Supply chain vulnerability  
- Ineffective escalation of quality risks  

Internal alignment is strong, but **project management sophistication and digital adoption** must improve.

---

# ‚ö†Ô∏è 4. Operational & Project-Based Problems

## **Operational Issues**
- **Quality Control Failures** (aseptic lapses, contamination)  
- **Weak Quality Unit (QU)** authority and resourcing  
- **Environmental Monitoring Deficiencies**  
- **Outdated digitalisation across plants**  
- **Dependence on specific markets and raw material regions**  

These have led to:
- Import alerts  
- Product recalls  
- Financial penalties  
- Brand damage  

## **Project-Based Issues**
- R&D returns lower than expected  
- Limited innovation in high-value drugs  
- Weak risk assessment in project execution  
- Coordination issues across teams  
- Inconsistent adoption of project management practices  

---

# üß© 5. Value Chain Analysis & Improvement Opportunities

### **Inbound Logistics**
- Diversify sourcing  
- Improve supplier auditing  
- Enhance API procurement forecasting  

### **Operations**
- Strengthen aseptic procedures  
- Implement digital batch records  
- Improve preventive maintenance  
- Increase automation  

### **Outbound Logistics**
- Digitise distribution visibility  
- Strengthen global channel integration  

### **Marketing & Sales**
- Improve transparency around quality actions  
- Leverage digital channels for patient engagement  

### **Service**
- Build patient education programs  
- Improve complaint tracking  

---

# üöÄ 6. Proposed Improvements

### **1. Strengthen the Quality Management System (QMS)**
- Adopt ISO 9001 alignment  
- Increase QU authority and resourcing  
- Improve environmental monitoring  
- Implement digital QMS tools  

### **2. R&D Realignment**
- Focus on specific therapeutic niches  
- Strengthen capability for complex generics  
- Build academic + industry partnerships  
- Improve portfolio risk‚Äìreturn balance  

### **3. Project Management Modernisation**
- Standardise project methodology  
- Improve risk identification and mitigation  
- Track milestones digitally  
- Enable cross-functional collaboration  

### **4. Digital Transformation**
- Deploy IoT sensors for real-time quality data  
- Implement MES (Manufacturing Execution Systems)  
- Use predictive maintenance  
- Improve data integrity practices  

### **5. Cultural & Continuous Improvement**
- Increase employee involvement in Kaizen  
- Regular training and development  
- Benchmark best practices (Pfizer, Novartis)  

---

# üå± Part B ‚Äî Reflective Learning

Your reflection highlights:

- Strong interest in **layout design** within operations  
- Appreciation of trade-offs between flexibility and efficiency  
- Recognition of the link between **product design, process design, and layout**  
- Broader understanding of how layout principles apply across service and manufacturing industries  

This demonstrates growth in **systems thinking**, **visual problem-solving**, and **operational design awareness**.

---

# üß† Skills Demonstrated

- Operational strategy evaluation  
- Hayes & Wheelwright maturity assessment  
- Quality and compliance analysis  
- Value chain analysis  
- Lean and continuous improvement  
- Project management diagnostic  
- Root cause and risk analysis  
- Reflective learning  

---

# üìÑ Full Report  
üëâ **[Open OPM.docx](OPM.docx)**  

---
